Results 31 to 40 of about 28,042 (215)

Table_1_Chronic Kidney Disease Increases Risk of Incident HFrEF Following Percutaneous Coronary Intervention.docx

, 2022
BackgroundChronic kidney disease (CKD) is very common in patients who are at a high risk of developing incident heart failure with reduced ejection fraction (HFrEF).
Ziling Mai (10067557), Shiqun Chen (4773258), Sijia Yu (10067566), Wenguang Lai (10067560), Zhidong Huang (8969360), Jin Liu (12833), Dachuan Guo (472460), Yun Xie (293668), Haozhang Huang (10198505), Yang Zhou (65942), Xiaoli Zhao (118708), Qiang Li (8118), Huanqiang Li (10067554), Haiyan Wei (1613839), Hongyu Lu (3203412), Yong Liu (6908), Shanggang Li (11716139)   +16 more
core   +1 more source

From Mouse Models to Patients: A Comparative Bioinformatic Analysis of HFpEF and HFrEF [PDF]

, 2023
Heart failure (HF) represents an immense health burden with currently no curative therapeutic strategies. Study of HF patient heterogeneity has led to the recognition of HF with preserved (HFpEF) and reduced ejection fraction (HFrEF) as distinct ...
Lanzer, Jan David
core   +1 more source

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

British Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić, Yusuf Ziya Sener, Marijana Vučković, Joseph Edgar Blais, Almir Fajkić, Emina Sher, Mislav Radić, Josipa Radić   +7 more
wiley   +1 more source

Pediatric Heart Failure Pharmacotherapy: Transformative Insights for the Future

Reviews in Cardiovascular Medicine
This review aims to summarize the status and future directions of pediatric heart failure (HF) pharmacotherapy. Notably, managing HF in children presents unique challenges due to heterogeneous etiologies and a longstanding paucity of pediatric-specific ...
Bibhuti B Das
doaj   +1 more source

Consequences of group III/IV afferent feedback and respiratory muscle work on exercise tolerance in heart failure with reduced ejection fraction

Experimental Physiology, 2023
Exercise intolerance and exertional dyspnoea are the cardinal symptoms of heart failure with reduced ejection fraction (HFrEF). In HFrEF, abnormal autonomic and cardiopulmonary responses arising from locomotor muscle group III/IV afferent feedback is one
Joshua R. Smith, Jonathon W. Senefeld, Kathryn F. Larson, Michael J. Joyner   +3 more
doaj   +1 more source

Table_2_Chronic Kidney Disease Increases Risk of Incident HFrEF Following Percutaneous Coronary Intervention.docx

, 2022
BackgroundChronic kidney disease (CKD) is very common in patients who are at a high risk of developing incident heart failure with reduced ejection fraction (HFrEF).
Ziling Mai (10067557), Shiqun Chen (4773258), Sijia Yu (10067566), Wenguang Lai (10067560), Zhidong Huang (8969360), Jin Liu (12833), Dachuan Guo (472460), Yun Xie (293668), Haozhang Huang (10198505), Yang Zhou (65942), Xiaoli Zhao (118708), Qiang Li (8118), Huanqiang Li (10067554), Haiyan Wei (1613839), Hongyu Lu (3203412), Yong Liu (6908), Shanggang Li (11716139)   +16 more
core   +1 more source

Coronary Flow in Hypertrophic Obstructive Cardiomyopathy—Immediate Effects of Alcohol Septal Ablation

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Hypertrophic cardiomyopathy is associated with alterations in coronary microvascular function which have variable pathophysiologic mechanisms, and variable reversibility acutely and chronically following alcohol septal ablation (ASA).
Vojko V. Misevic, Ana N. Golocevac, Kosta S. Krupnikovic, Stefan B. Timcic, Natalija B. Arnautovic, Dragana D. Radoicic, Milan R. Dobric, Aleksandar D. Mandic, Stefan S. Zivkovic, Aleksa D. Obradovic, Vladimir D. Mihajlovic, Natalija R. Odanovic, Ivan S. Ilic   +12 more
wiley   +1 more source

Combining New Classes of Drugs for HFrEF: from Trials to Clinical Practice

, 2021
Pharmacological approach to heart failure with reduced ejection fraction (HFrEF) is evolving, as recently published large randomized clinical trials have implemented the disposal of HFrEF treatments with four new classes of drugs, namely angiotensin ...
Sinagra, Gianfranco, Pagura, Linda, Stolfo, Davide, Fabris, Enrico, Savarese, Gianluigi, Rapezzi, Claudio, Ferrari, Roberto, Merlo, Marco   +7 more
core   +2 more sources

Ivabradine in Heart Failure with Reduced Ejection Fraction (HFrEF): A Narrative Review of Clinical Outcomes

Jurnal Manajemen dan Pelayanan Farmasi
Background: Therapy for heart failure with reduced ejection fraction (HFrEF) patients is complex, involving several combinations of treatments, but there are still some problems, such as rehospitalization, reduced ejection fraction values, increased ...
Rizky Hidayaturahmah, Erin Khoerunisa, Nisa Yulianti Suprahman, Fia Novitasari   +3 more
doaj   +1 more source

Exercise-induced pulmonary hypertension in HFpEF and HFrEF: Different pathophysiologic mechanism behind similar functional impairment

, 2022
Pathophysiological mechanisms behind cardio-pulmonary impairment in heart failure (HF) with reduced (HFrEF) and preserved (HFpEF) ejection fraction are likely different.
Dini, Frank L., Pugliese, Nicola Riccardo, Mazzola, Matteo, Masi, Stefano, Madonna, Rosalinda, Gargani, Luna, De Biase, Nicolò, Taddei, Stefano, De Caterina Raffaele   +8 more
core   +1 more source